News from Nektar Therapeutics A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages.

Latest

$codeDebug.log("output array of get country targets countryT

Nov 27, 2017, 16:37 ET Nektar to Webcast Presentation at the Piper Jaffray 29th Annual Healthcare Conference in New York City $codeDebug.log("output array of get country targets countryT

Nektar Therapeutics (Nasdaq: NKTR) announced today that its corporate presentation will be webcast at the upcoming Piper Jaffray 29th Annual...


$codeDebug.log("output array of get country targets countryT

Nov 22, 2017, 16:15 ET Nektar Announces Key Executive Promotions to Drive the Continued Growth of the Company's Immuno-Oncology Pipeline $codeDebug.log("output array of get country targets countryT

Nektar Therapeutics (Nasdaq: NKTR) announced today several promotions on its executive leadership team: - Stephen Doberstein, Ph.D.,...


$codeDebug.log("output array of get country targets countryT

Nov 11, 2017, 17:54 ET First Data for NKTR-214 in Combination with OPDIVO® (nivolumab) for Patients with Stage IV Melanoma, Renal Cell Carcinoma and Non-Small Cell Lung Cancers, Including Patients with PD-L1 Negative Status, Revealed at SITC 2017 $codeDebug.log("output array of get country targets countryT

Nektar Therapeutics (Nasdaq: NKTR) and Bristol-Myers Squibb (NYSE: BMY) today announced the first presentation of data from the PIVOT-02 Phase 1/2...


$codeDebug.log("output array of get country targets countryT

Nov 10, 2017, 08:09 ET Nektar to Webcast Presentation at Jefferies 2017 London Healthcare Conference $codeDebug.log("output array of get country targets countryT

Nektar Therapeutics (Nasdaq: NKTR) announced today that its corporate presentation will be webcast at the upcoming Jefferies 2017 London Healthcare...


$codeDebug.log("output array of get country targets countryT

Nov 07, 2017, 16:10 ET Nektar Therapeutics Reports Financial Results for the Third Quarter of 2017 $codeDebug.log("output array of get country targets countryT

Nektar Therapeutics (Nasdaq: NKTR) today reported its financial results for the third quarter ended September 30, 2017. Cash and investments in...


$codeDebug.log("output array of get country targets countryT

Nov 07, 2017, 08:10 ET New Data Featuring Nektar Therapeutics' Wholly-Owned Immuno-Oncology Pipeline to be Presented at the 2017 Society for Immunotherapy of Cancer 32nd Annual Meeting $codeDebug.log("output array of get country targets countryT

Nektar Therapeutics (Nasdaq: NKTR) today announced that new clinical data will be presented for NKTR-214, Nektar's lead immuno-oncology candidate,...


$codeDebug.log("output array of get country targets countryT

Nov 07, 2017, 08:00 ET Nektar Therapeutics Presents Preclinical Data on NKTR-358, a First-in-Class Regulatory T Cell Stimulator, at 2017 American College of Rheumatology Annual Meeting $codeDebug.log("output array of get country targets countryT

Nektar Therapeutics (Nasdaq: NKTR) today announced it is presenting preclinical data on NKTR-358, a potential first-in-class resolution therapeutic...


$codeDebug.log("output array of get country targets countryT

Oct 31, 2017, 18:41 ET Nektar to Announce Financial Results for the Third Quarter of 2017 on Tuesday, November 7, 2017, After Close of U.S.-Based Financial Markets $codeDebug.log("output array of get country targets countryT

Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the third quarter ended September 30, 2017, on Tuesday, November 7,...


$codeDebug.log("output array of get country targets countryT

Sep 21, 2017, 16:30 ET Nektar Therapeutics Appoints Biotechnology Executive Jeff Ajer as New Board Member $codeDebug.log("output array of get country targets countryT

Nektar Therapeutics (Nasdaq: NKTR) today announced that Jeff Ajer, Executive Vice President and Chief Commercial Officer of BioMarin, has been...


$codeDebug.log("output array of get country targets countryT

Sep 20, 2017, 07:24 ET Nektar Therapeutics Announces Seven Abstracts Accepted for Presentation at 2017 Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting $codeDebug.log("output array of get country targets countryT

Nektar Therapeutics (Nasdaq: NKTR) today announced that new data across its wholly-owned immuno-oncology (I-O) portfolio will be presented at the...


$codeDebug.log("output array of get country targets countryT

Sep 12, 2017, 09:00 ET Nektar Therapeutics Initiates PROPEL Clinical Study to Evaluate Combination of NKTR-214, a CD122-Biased Agonist, with TECENTRIQ® (atezolizumab) or KEYTRUDA® (pembrolizumab) $codeDebug.log("output array of get country targets countryT

Nektar Therapeutics (Nasdaq: NKTR) today announced that it has begun dosing in the PROPEL clinical study which will evaluate the efficacy and...


$codeDebug.log("output array of get country targets countryT

Sep 06, 2017, 18:00 ET Nektar Therapeutics Presents Clinical Data from Phase 3 SUMMIT-07 Study of NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2017 PAINWeek® $codeDebug.log("output array of get country targets countryT

Nektar Therapeutics (Nasdaq: NKTR) today presented clinical data from the SUMMIT-07 Phase 3 study of NKTR-181, a first-in-class opioid analgesic to...


$codeDebug.log("output array of get country targets countryT

Sep 06, 2017, 09:15 ET Nektar Therapeutics' President and CEO, Howard W. Robin, To Present at the 2017 Morgan Stanley Global Healthcare Conference in New York City $codeDebug.log("output array of get country targets countryT

Nektar Therapeutics' (Nasdaq: NKTR) President and Chief Executive Officer, Howard W. Robin, is scheduled to present at the upcoming 2017 Morgan...


$codeDebug.log("output array of get country targets countryT

Aug 30, 2017, 09:00 ET Nektar Therapeutics to Present Clinical Data from Phase 3 SUMMIT-07 Study of NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at PAINWeek® $codeDebug.log("output array of get country targets countryT

Nektar Therapeutics (Nasdaq: NKTR) will present clinical data from the SUMMIT-07 Phase 3 efficacy and safety study of NKTR-181, a first-in-class...


$codeDebug.log("output array of get country targets countryT

Aug 08, 2017, 16:10 ET Nektar Therapeutics Reports Financial Results for the Second Quarter of 2017 $codeDebug.log("output array of get country targets countryT

Nektar Therapeutics (Nasdaq: NKTR) today reported its financial results for the second quarter ended June 30, 2017. Cash and investments in...


$codeDebug.log("output array of get country targets countryT

Aug 02, 2017, 17:52 ET Nektar to Announce Financial Results for the Second Quarter of 2017 on Tuesday, August 8, 2017, After Close of U.S.-Based Financial Markets $codeDebug.log("output array of get country targets countryT

Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the second quarter ended June 30, 2017, on Tuesday, August 8, 2017,...


$codeDebug.log("output array of get country targets countryT

Jul 18, 2017, 08:00 ET Nektar Announces Topline Data from Human Abuse Potential Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain $codeDebug.log("output array of get country targets countryT

Nektar Therapeutics (NASDAQ: NKTR) announced positive topline results from an oral Human Abuse Potential (HAP) study of NKTR-181, a first-in-class...


$codeDebug.log("output array of get country targets countryT

Jul 10, 2017, 09:00 ET Nektar Presents New Preclinical Data for NKTR-358, a First-in-Class Regulatory T Cell Stimulator, at 13th World Congress of Inflammation in London $codeDebug.log("output array of get country targets countryT

Nektar Therapeutics (NASDAQ: NKTR) today announced positive preclinical results for NKTR-358, a first-in-class resolution therapeutic for...


$codeDebug.log("output array of get country targets countryT

Jun 06, 2017, 16:15 ET Nektar to Webcast Presentation at Jefferies 2017 Global Healthcare Conference in New York City $codeDebug.log("output array of get country targets countryT

Nektar Therapeutics (Nasdaq: NKTR) announced today that its corporate presentation will be webcast at the upcoming Jefferies 2017 Global Healthcare...


$codeDebug.log("output array of get country targets countryT

Jun 05, 2017, 09:00 ET Nektar Presents New Clinical Data from Two Studies of NKTR-214, a CD122-Biased Agonist, at 2017 American Society of Clinical Oncology (ASCO) Annual Meeting $codeDebug.log("output array of get country targets countryT

Nektar Therapeutics (Nasdaq: NKTR) today announced that it presented new findings from two Phase 1 clinical studies of NKTR-214, Nektar's lead...


$codeDebug.log("output array of get country targets countryT

May 22, 2017, 09:00 ET New Research Collaboration between Nektar and Takeda to Explore Combination Cancer Therapy Approaches with NKTR-214, a CD122-Biased Agonist, and Five Takeda Cancer Therapy Compounds $codeDebug.log("output array of get country targets countryT

Nektar Therapeutics (NASDAQ: NKTR) announced today that Takeda Pharmaceutical Company Limited (TSE: 4502) and Nektar have entered into a research...


$codeDebug.log("output array of get country targets countryT

May 15, 2017, 16:15 ET Nektar to Webcast Presentation at UBS Global Healthcare Conference 2017 in New York $codeDebug.log("output array of get country targets countryT

Nektar Therapeutics (Nasdaq: NKTR) announced today that its corporate presentation will be webcast at the upcoming UBS Global Healthcare Conference...


$codeDebug.log("output array of get country targets countryT

May 09, 2017, 16:10 ET Nektar Therapeutics Reports Financial Results for the First Quarter of 2017 $codeDebug.log("output array of get country targets countryT

Nektar Therapeutics (Nasdaq: NKTR) today reported its financial results for the first quarter ended March 31, 2017. Cash and investments in...


$codeDebug.log("output array of get country targets countryT

May 03, 2017, 09:15 ET Nektar Appoints Brian L. Kotzin, M.D. as Head of Clinical Development for Nektar's Immunology Program $codeDebug.log("output array of get country targets countryT

Nektar Therapeutics (Nasdaq: NKTR) today announced the appointment of Brian Kotzin, M.D. as Head of Clinical Development for Nektar's Immunology...


$codeDebug.log("output array of get country targets countryT

May 02, 2017, 09:15 ET Nektar to Announce Financial Results for the First Quarter of 2017 on Tuesday, May 9, 2017, After Close of U.S.-Based Financial Markets $codeDebug.log("output array of get country targets countryT

Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the first quarter ended March 31, 2017, on Tuesday, May 9, 2017, after...